Literature DB >> 8109211

An 18-month vitreous fluorophotometric follow-up study in juvenile diabetics.

J M Benitez del Castillo1, A Castillo, J Garcia Sanchez, J L Ruibal, F Reverte, J M Ibarra.   

Abstract

The authors assessed a fluorophotometry follow-up study of 18 months in 24 juvenile insulin-dependent diabetic patients with no retinopathy. The initial duration of diabetes was 5.96 +/- 3.44 years and the glycosylated hemoglobin (HbA1c) was 10.12 +/- 2.27%. The baseline Vitreous Penetration Ratio transmittance value (VPRt) was 4.13 +/- 1.31 x 10-6 min-1 and after 18 months was 5.36 +/- 1.85 x 10-6 min-1, yielding a statistically significant difference (p < 0.01). The average HbA1c during the follow-up term was 9.80 +/- 1.72%. VPRt values were significantly correlated with the duration of diabetes and HbA1c. During the follow-up 3 patients developed foveal background diabetic retinopathy with respect to a high initial VPRt value (6.22 +/- 0.27 x 10-6 min-1), nevertheless, the other 7 patients with high baseline VPRt did not do so. We suggest that vitreous fluorophotometry could be a beneficial procedure in the management of insulin-dependent diabetic patients; however, there is not a cut-off value for VPRt values to help distinguish patients prone to develop retinopathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109211     DOI: 10.1111/j.1755-3768.1993.tb04655.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  2 in total

1.  Permeability of the blood-retinal barrier in healthy humans. European Concerted Action on Ocular Fluorometry.

Authors:  H J Van Schaik; B Heintz; M Larsen; E Leite; V Rosas; R Schalnus; J A Van Best
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

2.  Analysis of the blood-retinal barrier: its relation to clinical and metabolic factors and progression to retinopathy in juvenile diabetics. A 4-year follow-up study.

Authors:  A Castillo; J M Benitez del Castillo; D Diaz; O Sayagues; J L Ruibal; J Garcia-Sanchez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-04       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.